Corona Remedies IPO Analyzed

The Corona Remedies Initial Public Offering (IPO) has seen strong investor interest. As of Tuesday, December 9th, 2025, the IPO was significantly oversubscribed, indicating high demand for the company’s shares. Investors placed bids for 4,26,66,148 shares, far exceeding the initial offer of 45,71,882 shares. This level of interest is a key signal about the company’s potential.

Key Points

• IPO oversubscribed 9.33 times, showing significant investor demand.
• 4,26,66,148 bids received versus the 45,71,882 share offer.
• IPO raised Rs 194.85 crore through anchor investors.
• Company focuses on healthcare products in India’s western zone.
• Revenue primarily from women’s health and diabetes treatments.
• Strong financial performance: Rs 46.20 crore net profit.

The IPO was open for bidding from December 8th to December 10th, 2025, with a price range of Rs 1,008 to Rs 1,062 per share. It’s a complete sale of shares by existing owners. This strong response suggests confidence in Corona Remedies’ future.

Corona Remedies is a company based in India, developing and selling medicines in areas like women’s health, diabetes, pain relief, and treating urinary problems. Their biggest source of income comes from selling products related to women’s health and diabetes, accounting for about half of their business.

As of June 30th, 2025, the company had a lot of different medicines (brands) – 71 in total – covering various health issues. Most of their business, 96.34%, is within India, with a smaller amount sold abroad (3.66%). They are particularly successful in the western part of India, including states like Gujarat, Maharashtra, and Madhya Pradesh.

Before the IPO even started on December 5th, 2025, Corona Remedies already raised Rs 194.85 crore by selling shares to big investors called “anchor investors.” These investors bought 18.34 million shares at a price of Rs 1,062 each.

Recently, the company reported good financial results for the three months ending September 30th, 2025. They made a profit of Rs 46.20 crore and sold products worth Rs 346.54 crore.

Ultimately, this IPO signals a positive outlook for Corona Remedies’ continued growth and market position within the Indian pharmaceutical industry.